HRP20100127T1 - Višečestični oblici - Google Patents
Višečestični oblici Download PDFInfo
- Publication number
- HRP20100127T1 HRP20100127T1 HR20100127T HRP20100127T HRP20100127T1 HR P20100127 T1 HRP20100127 T1 HR P20100127T1 HR 20100127 T HR20100127 T HR 20100127T HR P20100127 T HRP20100127 T HR P20100127T HR P20100127 T1 HRP20100127 T1 HR P20100127T1
- Authority
- HR
- Croatia
- Prior art keywords
- multiparticle
- oxycodone
- forms according
- pharmaceutical composition
- plasticizer
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 16
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims abstract 14
- 229960002085 oxycodone Drugs 0.000 claims abstract 13
- 239000003607 modifier Substances 0.000 claims abstract 11
- 230000035699 permeability Effects 0.000 claims abstract 11
- 229920001577 copolymer Polymers 0.000 claims abstract 10
- 239000000314 lubricant Substances 0.000 claims abstract 9
- 239000004014 plasticizer Substances 0.000 claims abstract 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 3
- 238000013270 controlled release Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 7
- 239000004615 ingredient Substances 0.000 claims 6
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229940049654 glyceryl behenate Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920003156 Eudragit® RL PO Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol group Chemical group C(CCCCCCCCCCCCCCC)O BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 229920003160 Eudragit® RS PO Polymers 0.000 claims 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 1
- 229940105606 oxycontin Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ekstrudirani iz otopine, višečestični oblici sa kontroliranim oslobađanjem, naznačeni time što sadrže (a) oksikodon, (b) amonijev metakrilat kopolimer netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza. Patent sadrži još 26 patentnih zahtjeva.
Claims (27)
1. Ekstrudirani iz otopine, višečestični oblici sa kontroliranim oslobađanjem, naznačeni time što sadrže (a) oksikodon, (b) amonijev metakrilat kopolimer netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza.
2. Višečestični oblici prema patentnom zahtjevu 1, naznačeni time što je oksikodon prisutan kao farmaceutski prihvatljiva sol.
3. Višečestični oblici prema patentnom zahtjevu 2, naznačeni time što je oksikodon prisutan kao oksikodon hidroklorid.
4. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeni time što je plastifikator izabran od cetil alkohola, stearil alkohola, cetostearil alkohola, sorbitola, saharoze, visoke molekularne težine - polietilen glikola, dibutil sebacata, tributil citrata, trietil citrata, propilen glikola i polietilen glikola niske molekularne težine.
5. Višečestični oblici prema patentnom zahtjevu 4, naznačeni time što je plastifikator stearil alkohol.
6. Višečestični oblici prema patentnom zahtjevu 4, naznačeni time što je plastifikator polietilen glikol visoke molekularne težine.
7. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeni time što je lubrikant izabran od gliceril behenata, talka i silikon dioksida.
8. Višečestični oblici prema patentnom zahtjevu 7, naznačeni time što je lubrikant gliceril behenat.
9. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeni time što je lubrikant stearinska kiselina ili stearat sol.
10. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeni time što je modifikator vodopropusnosti vodopropusni amonijev metakrilat kopolimer.
11. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 10, naznačeni time što je modifikator vodopropusnosti - Eudragit RL PO.
12. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeni time što su postotne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 3 do 50
netopljivi amonijev metakrilat kopolimer 25 do 85
plastifikator 1 do 30
lubrikant 1 do 25
modifikator vodopropusnosti 1 do 40.
13. Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su postotne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 5 do 40
netopljjivi amonijev metakrilat kopolimer 35 do 75
plastifikator 3 do 25
lubrikant 2 do 25
modifikator vodopropusnosti 1 do 30.
14. Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su procentne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na osnovu ukupne težine pet sastojaka:
oksikodon kao hidroklorid 7.5 do 35
netopljiv amonijev metakrilat kopolimer 50 do 65
plastifikator 5 do 15
lubrikant 2 do 25
modifikator vodopropusnosti 1 do 20.
15. Višečestični oblici prema patentnom zahtjevu 1, naznačeni time što sadrže oksikodon, Eudragit RS PO, stearil alkohol, gliceril behenat i Eudragit RL PO.
16. Farmaceutska kompozicija u obliku jedinične doze, naznačena time što sadrži višečestične oblike prema bilo kojem od prethodnih patentnih zahtjeva.
17. Farmaceutska kompozicija prema patentnom zahtjevu 16, naznačena time što jedinična doza osigurava dozu oksikodona koja je dovoljna da osigura analgeziju humanom pacijentu.
18. Farmaceutska kompozicija prema patentnom zahtjevu 17, naznačena time što je bioekvivalentna OxyContin® tabletama.
19. Farmaceutska kompozicija prema patentnom zahtjevu 17 ili 18, naznačena time što je dovoljna doza oksikodona 5 do 400 mg.
20. Farmaceutska kompozicija prema patentnom zahtjevu 19, naznačena time što je jedinična doza oksikodona 5 mg, 10 mg, 20 mg, 40 mg, 80 mg ili 160 mg.
21. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16 do 20, naznačena time što je u obliku kapsule sa punjenjem od navedenih višečestičnih oblika.
22. Farmaceutska kompozicija prema patentnom zahtjevu 21, naznačena time što su višečestični oblici punjeni u tvrde želatinozne kapsule, pri čemu svaka od tih kapsula sadrži jediničnu dozu.
23. Farmaceutska kompozicija prema patentnom zahtjevu 22, naznačena time što je težina punjenja u kapsuli u opsegu od 120 do 500 mg.
24. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16 do 23, naznačena time što je namjenjena za primjenu u intervalima od 12 sati.
25. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16, 17 i 19 do 23, naznačena time što je namjenjena za primjenu u intervalima od 24 sata.
26. Postupak za pripremu višečestičnih oblika prema patentnom zahtjevu 1 naznačen time što sadrži pripremu mješavine koja sadrži (a) oksikodon, (b) amonijev metakrilat kopolimer koji je netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza; i ekstruziju mješavine.
27. Farmaceutska kompozicija naznačena time što sadrži višečestične oblike prema bilo kojem od patentnih zahtjeva 1 do 15 i višečestične oblike antagonista oksikodona.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0315137A GB0315137D0 (en) | 2003-06-27 | 2003-06-27 | Multiparticulates |
| GB0403102A GB0403102D0 (en) | 2004-02-12 | 2004-02-12 | Multiparticulates |
| GB0413454A GB0413454D0 (en) | 2004-06-16 | 2004-06-16 | Multiparticulates |
| PCT/GB2004/002705 WO2005000310A1 (en) | 2003-06-27 | 2004-06-23 | Multiparticulates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100127T1 true HRP20100127T1 (hr) | 2010-04-30 |
Family
ID=33556051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100127T HRP20100127T1 (hr) | 2003-06-27 | 2010-03-08 | Višečestični oblici |
| HRP20140635TT HRP20140635T1 (hr) | 2003-06-27 | 2014-07-04 | Multiäśestice |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140635TT HRP20140635T1 (hr) | 2003-06-27 | 2014-07-04 | Multiäśestice |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1644002B1 (hr) |
| JP (2) | JP5348841B2 (hr) |
| KR (1) | KR101116518B1 (hr) |
| AR (1) | AR044935A1 (hr) |
| AT (1) | ATE453394T1 (hr) |
| AU (1) | AU2004251481B2 (hr) |
| BR (1) | BRPI0411901B1 (hr) |
| CA (1) | CA2530385C (hr) |
| CY (2) | CY1109917T1 (hr) |
| DE (1) | DE602004024888D1 (hr) |
| DK (2) | DK1889621T3 (hr) |
| EA (1) | EA013424B1 (hr) |
| ES (2) | ES2490598T3 (hr) |
| HR (2) | HRP20100127T1 (hr) |
| IL (1) | IL172730A (hr) |
| MX (1) | MXPA05013799A (hr) |
| MY (1) | MY176831A (hr) |
| NO (1) | NO20060443L (hr) |
| NZ (1) | NZ544181A (hr) |
| PE (1) | PE20050286A1 (hr) |
| PL (2) | PL1644002T3 (hr) |
| PT (2) | PT1644002E (hr) |
| SI (2) | SI1889621T1 (hr) |
| TW (1) | TWI357815B (hr) |
| WO (1) | WO2005000310A1 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ505193A (en) | 1997-12-22 | 2003-03-28 | Euro Celtique S | Opioid agonist/antagonist combinations |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| DK2425825T3 (en) | 2002-04-05 | 2017-02-20 | Euro Celtique Sa | Pharmaceutical preparation containing oxycodone and naloxone |
| DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| CN101132772B (zh) * | 2005-01-28 | 2012-05-09 | 欧洲凯尔特公司 | 耐醇剂型 |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| RU2433817C2 (ru) * | 2006-01-21 | 2011-11-20 | Эбботт Гмбх Унд Ко.Кг | Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| JP5452236B2 (ja) * | 2007-03-02 | 2014-03-26 | ファーナム・カンパニーズ・インコーポレーテッド | ロウ様物質を用いた徐放性組成物 |
| AU2008262545B2 (en) | 2007-05-25 | 2013-12-05 | Indivior Uk Limited | Sustained delivery formulations of risperidone compounds |
| NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| US9072670B2 (en) | 2007-10-19 | 2015-07-07 | Otsuka Pharmaceutical Co., Ltd. | Matrix-type pharmaceutical solid preparation |
| JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
| AU2009294308B2 (en) * | 2008-09-18 | 2013-05-30 | Purdue Pharma L.P. | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| MY152279A (en) | 2009-03-10 | 2014-09-15 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| WO2011099985A1 (en) * | 2010-02-11 | 2011-08-18 | Harry Leider | Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| CN104684548A (zh) | 2012-07-06 | 2015-06-03 | 埃格勒特有限责任公司 | 防止滥用的控释药物组合物 |
| JP2016525138A (ja) | 2013-07-23 | 2016-08-22 | ユーロ−セルティーク エス．エイ． | 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| JPH11508224A (ja) * | 1990-08-09 | 1999-07-21 | エンドコン・インコーポレーテッド | 多重ドラッグデリバリーシステム |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| EP0744941B1 (en) * | 1994-02-16 | 2003-06-04 | Abbott Laboratories | Process for preparing fine particle pharmaceutical formulations |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE69625822T2 (de) * | 1995-05-01 | 2003-06-05 | Sam Yang Co., Ltd. | Implantierbare, bioresorbierbare membran und verfahren zu ihrer herstellung |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| AU3404997A (en) * | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
| DK1623703T3 (da) * | 1999-10-29 | 2011-11-28 | Euro Celtique Sa | Hydrocodonformuleringer med kontrolleret frigivelse |
| ES2539945T3 (es) * | 2000-02-08 | 2015-07-07 | Euro-Celtique S.A. | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
| FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
| EP1503731A1 (en) * | 2002-05-07 | 2005-02-09 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| CN1741792A (zh) * | 2003-01-24 | 2006-03-01 | 控制递送系统有限公司 | 经眼部递送肾上腺素能剂的持续释放系统和方法 |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
-
2004
- 2004-06-18 TW TW093117618A patent/TWI357815B/zh not_active IP Right Cessation
- 2004-06-23 EP EP04743056A patent/EP1644002B1/en not_active Expired - Lifetime
- 2004-06-23 PL PL04743056T patent/PL1644002T3/pl unknown
- 2004-06-23 KR KR1020057024940A patent/KR101116518B1/ko not_active Expired - Fee Related
- 2004-06-23 AT AT04743056T patent/ATE453394T1/de active
- 2004-06-23 PT PT04743056T patent/PT1644002E/pt unknown
- 2004-06-23 SI SI200432174T patent/SI1889621T1/sl unknown
- 2004-06-23 WO PCT/GB2004/002705 patent/WO2005000310A1/en active Application Filing
- 2004-06-23 ES ES07013702.1T patent/ES2490598T3/es not_active Expired - Lifetime
- 2004-06-23 EA EA200600111A patent/EA013424B1/ru not_active IP Right Cessation
- 2004-06-23 DK DK07013702.1T patent/DK1889621T3/da active
- 2004-06-23 PL PL07013702T patent/PL1889621T3/pl unknown
- 2004-06-23 CA CA2530385A patent/CA2530385C/en not_active Expired - Fee Related
- 2004-06-23 EP EP07013702.1A patent/EP1889621B1/en not_active Expired - Lifetime
- 2004-06-23 DE DE602004024888T patent/DE602004024888D1/de not_active Expired - Lifetime
- 2004-06-23 AU AU2004251481A patent/AU2004251481B2/en not_active Ceased
- 2004-06-23 PT PT70137021T patent/PT1889621E/pt unknown
- 2004-06-23 DK DK04743056.6T patent/DK1644002T3/da active
- 2004-06-23 ES ES04743056T patent/ES2337468T3/es not_active Expired - Lifetime
- 2004-06-23 MX MXPA05013799A patent/MXPA05013799A/es active IP Right Grant
- 2004-06-23 BR BRPI0411901-0A patent/BRPI0411901B1/pt not_active IP Right Cessation
- 2004-06-23 JP JP2006516468A patent/JP5348841B2/ja not_active Expired - Fee Related
- 2004-06-23 SI SI200431330T patent/SI1644002T1/sl unknown
- 2004-06-23 NZ NZ544181A patent/NZ544181A/en not_active IP Right Cessation
- 2004-06-24 PE PE2004000617A patent/PE20050286A1/es not_active Application Discontinuation
- 2004-06-25 AR ARP040102264A patent/AR044935A1/es not_active Application Discontinuation
- 2004-06-25 MY MYPI20042516A patent/MY176831A/en unknown
-
2005
- 2005-12-21 IL IL172730A patent/IL172730A/en active IP Right Grant
-
2006
- 2006-01-27 NO NO20060443A patent/NO20060443L/no not_active IP Right Cessation
-
2010
- 2010-03-08 HR HR20100127T patent/HRP20100127T1/hr unknown
- 2010-03-19 CY CY20101100259T patent/CY1109917T1/el unknown
-
2013
- 2013-05-08 JP JP2013098685A patent/JP5960089B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 HR HRP20140635TT patent/HRP20140635T1/hr unknown
- 2014-07-31 CY CY20141100577T patent/CY1115415T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100127T1 (hr) | Višečestični oblici | |
| ES2260253T3 (es) | Composicion farmaceutica oral de liberacion controlada y absorcion prolongada. | |
| US5133974A (en) | Extended release pharmaceutical formulations | |
| ES2319266T3 (es) | Comprimidos efervescentes bucodispersables. | |
| ES2625092T3 (es) | Formas de dosificación orales resistentes a la adicción y método de uso de las mismas | |
| ES2642788T3 (es) | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos | |
| JP2008511604A5 (hr) | ||
| HRP960554A2 (en) | Pharmaceutical formulations | |
| ES2409069A2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| BRPI0610634A2 (pt) | combinação para a terapia de hiperplasia benigna da próstata | |
| BR112012025015B1 (pt) | Formulações farmacêuticas para tratamento de bexiga hiperativa. | |
| ES2680444T3 (es) | Forma de dosificación oral sólida de irinotecán para el tratamiento del cáncer | |
| US9387166B2 (en) | Controlled release oral dosage form comprising oxycodone | |
| JPH08208520A (ja) | 経口薬剤構成物 | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| CN103919715A (zh) | 含有甘磷酸胆碱或其盐的控释药物组合物及其制备方法 | |
| AU2015349896B2 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| AU2021204247A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| CA2804874C (en) | Formulations comprising coated fine particles | |
| ES2321908T3 (es) | Preparaciones farmaceuticas de liberacion prolongada independientemente del ph. | |
| JP2018526414A5 (hr) | ||
| JP6186139B2 (ja) | 口腔内速崩壊性錠剤 | |
| JP2019504859A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| ES2326251A1 (es) | Composiciones de ticlopidina de liberacion modificada. |